Health In Tech Secures $7M to Fuel AI Growth Amid Market Scrutiny

STUART, Fla. – March 27, 2026 – Health In Tech, Inc. (Nasdaq: HIT), an AI-focused InsurTech company, announced today the successful closing of a $7.0 million private investment, a move designed to supercharge its technological development and market expansion. However, the capital infusion, while celebrated by the company as a strategic win, was met with immediate turbulence on the market, highlighting the delicate balance between funding future growth and immediate shareholder value.

The financing, known as a private investment in public equity (PIPE), involved the issuance of 5.6 million new shares of common stock at a price of $1.25 per share. While the company secured the capital it sought from institutional and accredited investors, the announcement on March 25th prompted an 11.05% drop in its stock price, with at least one analyst subsequently lowering their price target. The market's reaction points directly to the deal's inherent trade-off: an approximate 9.8% dilution for existing shareholders in exchange for a war chest to accelerate the company's ambitions.

Fueling the AI Engine

Health In Tech's leadership has framed the financing as a critical step toward realizing its long-term vision. The company operates a sophisticated AI-enabled marketplace designed to simplify the complex world of self-funded health insurance for employers, a sector traditionally burdened by manual processes and opacity. The platform connects brokers, carriers, and administrators, aiming to automate everything from underwriting to claims.

"This financing strengthens our ability to accelerate the next phase of our platform development," said Tim Johnson, Chief Executive Officer of Health In Tech, in the official announcement. He emphasized that the capital is not just for maintenance but for aggressive innovation. "The additional capital will support key technology initiatives and help us bring new product capabilities to market that our clients have been actively requesting."

According to the company, the net proceeds are earmarked for several key areas: expanding sales distribution, advancing its core technology, and supporting new product development. A significant portion of this investment is expected to enhance its flagship eDIYBS platform, a web-based tool that leverages AI to provide brokers with medically underwritten, bindable quotes in as little as two minutes—a dramatic acceleration of a traditionally slow process. The company has also signaled plans to expand this AI-underwriting capability to serve larger employers and launch a new Three-Year Rate Stabilization Program later in 2026.

Johnson believes these enhancements will be pivotal. "As we continue expanding the functionality of our platform, we believe it will deepen customer engagement and support sustained, scalable revenue growth," he stated.

A Vote of Confidence Amid Market Jitters

Beyond the technological push, Health In Tech's management highlighted the strategic importance of the investors participating in the PIPE. Chief Financial Officer Julia Qian noted that the deal brings fresh capital and new partners to the table.

"The transaction introduces new long-term institutional investors to our shareholder base," Qian explained. "We believe this will enhance market visibility and support our broader capital markets strategy while providing flexibility to continue investing in our technology and growth initiatives." Attracting institutional money is often seen as a validation of a company's business model and future prospects, a signal that sophisticated investors see a clear path to profitability.

This vote of confidence comes as Health In Tech navigates a competitive and rapidly evolving industry. The global InsurTech market is projected to grow at a compound annual growth rate of over 26% through the next decade, while the AI in Healthcare market is also on an explosive trajectory. Health In Tech is one of many players vying for dominance, competing with firms like American Integrity Insurance Group and Kingsway Financial Services.

However, the company has carved out a distinct niche with its focus on AI-driven efficiency for self-funded employer plans. This strategic focus appears to be paying off. Despite the short-term negative stock reaction to the PIPE, Health In Tech's underlying business performance has been robust. In 2025, the company reported a remarkable 70.99% increase in revenue to $33.33 million and saw its adjusted EBITDA grow 81% year-over-year to $4.1 million. Looking ahead, the company has issued ambitious 2026 revenue guidance of $45 million to $50 million, projecting growth of 35% to 50%.

This strong financial trajectory provides crucial context for the $7.0 million financing. While the market may have flinched at the dilution, the capital injection equips a rapidly growing company with the resources needed to seize a larger share of a booming market. The challenge for Health In Tech will be to deploy this new capital effectively, translating technological enhancements into the sustained, scalable revenue growth that both its new and existing investors are counting on.